Now I point all of this out in empathy with most of you who aren’t in this profession and have limited options regarding your medical care. It’s a fact that most doctors will be unwilling to treat aging as some sort of illness. Not now. Not ever. So no matter what discoveries we make, if it involves meds , it’s going to be difficult.

Job Function* Applications/Software ManagerCEOConsultantCTO/Technology DirectorDirectorE-commerce DirectorFinancial Director/CFOInvestment Banker/Financial AnalystIT Operations ManagerIT StrategyLine of Business ManagerManaging DirectorManagementMarketing DirectorMarketing ManagerMIS/IT ManagerNetwork/Comms ManagerProject ManagerSales DirectorSales ManagerSenior ManagerSystems Development ManagerChief ExecutiveHead of DepartmentSenior Team MemberJunior Team MemberChairTrusteeVolunteerSupplier/consultantGovernmentFunderAirport Director/Airport General ManagerBrand Protection & ManagementCIO/IT DirectorCOO/Operations DirectorCorporate PackagingCTO/Technical DirectorLogistics/Supply ChainMarketingOther Please specifyPackagingPackaging & LabellingPackaging BuyerPackaging DesignPackaging DevelopmentPackaging EngineerPackaging InnovationsPackaging ServicesPackaging TechnologyPlant ManagementPresident/CEO/MDProduction/ManufacturingPurchasing/ProcurementQuality Assurance/Quality ControlR&DRegional DirectorVice PresidentAir Traffic ManagementAirline Route PlannerArchitectArchitectural TechnologistAssembly EngineeringAviationBuilding EngineerBuilding SurveyorBusiness DevelopmentCargo OperationsCash ManagementCFO/FinanceCFO/Finance DirectorChairmanChief AccountantChief Scientific OfficerCISO/Technical DirectorClinical ResearchCombat/Military PersonnelComercial ManagementCommercial ManagementComplianceConstructionCRO/Risk DirectorCruise OperationsCruise Ship Interior DesignDataDesign EngineeringDoctorDrillingDrug DiscoveryEngineeringEntertainmentExploration & ProductionFab (Fabrication Management)FacilitiesFinance ControlerFinancial ManagementFood & BeverageFranchisingGround HandlingGroup TreasurerHealth & SafetyHealth and SafetyHealthcare Trust ManagementHospital AdministratorHospital Manager/DirectorHotel OperationsHRHuman resourcesICU, CCU, and Respiratory CareInfection ControlInterior DesignInterior DesignerLandscape ArchitectLegalLicensingLogistics/SupplychainMaintenanceMarine OperationsMedical ImagingMeeical Manage/DirectorMetallurgyMiningNaval ArchitectOther (please specify)Others Please specifyPartner/Principal ArchitectPlanning & DevelopmentPort OperationsPRProcess EngineeringProject ManagementPurchasing/Procurement",QA/QC EngineeringQuantity SurveyorR and DRegulatory AffairsRehabilitationSafetySales & MarketingSecuritySenior ArchitectShipbuildingSubseaSubsea OperationsTest EngineeringTour/ Programme ManagementTraining

        We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the U.S. without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements. We have not previously submitted an NDA to the FDA or similar drug approval filings to comparable foreign regulatory authorities for any of our product candidates. We, and any future collaborators, must complete extensive pre-clinical development and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals.

        Zilucoplan is a potent synthetic macrocyclic peptide inhibitor of C5, which is a clinically validated target for patients with PNH. We are developing zilucoplan as a convenient, self-administered product that can be administered in a small daily, or less frequent, such as weekly, dose. We believe this approach will facilitate sustained hemolysis suppression, greatly reducing the possibility of breakthrough hemolysis in eculizumab naïve and eculizumab switch patients who were transfusion-independent on eculizumab. In addition, we believe self-administration will alleviate the significant time and cost burden associated with regular intravenous infusions by healthcare professionals, as well as reduce complications associated with IV infusions, including infections, thrombosis, and loss of venous access.

Following termination of service as an external director, a public company, a controlling shareholder thereof and any entity controlled by a controlling shareholder, may not grant any benefit, directly or indirectly, to any person who served as an external director of such public company, or to his or her spouse or child, including, not appointing such person, or his or her spouse or child, as an Office Holder of such public company or of any entity controlled by a controlling shareholder of such public company, not employing such person or his or her spouse or child and not receiving professional services for pay from such person, either directly or indirectly, including through a corporation controlled by such person, all until the lapse of two years from termination of office with respect to the external director, his or her spouse or child; and until the lapse of one year from termination of office with respect to other relatives of the former external director.

Aramchol was non-mutagenic in vitro in the Ames test and chromosomal aberrations test, each of which is a test to determine whether the subject chemical can cause mutations in the DNA of an organism. In addition, in bone marrow micronucleus test in male rats at a 2000 mg/kg oral dose (the maximum recommended dose in accordance with ICH S2 (R1)), Aramchol was not clastogenic, meaning it did not give rise to or induce disruption or breakages of chromosomes, nor was it aneugenic, meaning it did not cause the number of chromosomes in the nucleus of a cell to not be an exact multiple of the monoploid number of a particular species.

Thanks also for your comments on the extracts of magnolia, I am thinking of using it instead of Berberine for glucose control. I am also interested in its potential for adipogenesis (the subcutaneous, anti inflammatory kind). The only thing that remains as a question mark in my mind is the fact that honokiol can protect mitochondria, but also increase membrane permeability and cause apoptosis in cancer cells (via the transition pore). Here is the relevant study.

We may invest in the equity of foreign corporations that are PFICs or may own subsidiaries that own PFICs. If we are classified as a PFIC, under attribution rules, U.S. Holders will be subject to the PFIC rules with respect to their indirect ownership interests in such PFICs, such that a disposition of the ordinary shares of the PFIC or receipt by us of a distribution from the PFIC generally will be treated as a deemed disposition of such ordinary shares or the deemed receipt of such distribution by the U.S. Holder, subject to taxation under the PFIC rules. There can be no assurance that a U.S. Holder will be able to make a QEF election or a mark-to-market election with respect to PFICs in which we invest. Each U.S. Holder is encouraged to consult its own tax advisor with respect to tax consequences of an investment by us in a corporation that is a PFIC.

GGCAAAGACGGACTCAA-3′ and 3′-AGGAAGCTGAAGTCATAACCGCCA-5′; α-SMA: 5′-CGTACAACTGGTATTGTGCTGGAC-3′ and 3′- TGATGTCACGGACAATCTCACGCT-5′; and GAPDH: 5′-CGTGCCGCCTGGAGAAAC-3′ and 3′-AGTGGGAGTTGCTGTTGAAGTC-5′.

So I was so aggravated at my idiot doctor that I forgot to get the referral for the echo. So I’m just going to go soon and pay for it. Lol

Muñoz, P. et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood 111, 3653–3664 (2008).

"I LOVE this resource. Absolutely the best and most reliable single source of what’s going on that affects our business. THANKS!!"